Disease Information & Support


The Word:


Treating Specific Aggressive Subtypes

AIDS-Associated Lymphoma

Certain types of NHL are seen more often in people who have autoimmune deficiency syndrome (AIDS), including diffuse large B-cell lymphoma, Burkitt lymphoma and primary central nervous system lymphoma. Treatment outcome depends on how well AIDS is responding to therapy. Because AIDS already leads to low blood cell counts, chemotherapy must be carefully considered to determine whether the treatment's additional effect on blood levels can be managed. Improved treatment for human immunodeficiency virus (HIV) in recent years has helped reduce the number of people diagnosed with AIDS-associated NHL.

Anaplastic Large Cell Lymphoma

Anaplastic large cell lymphoma, most common in young people, usually starts in lymph nodes and can spread to the skin. But it can also start in the skin. A combination of radiation therapy and chemotherapy has proved to be an effective two-pronged approach to treating this subtype. Brentuximab vedotin, (Adcetris(R)) also known as SGN-35, is FDA approved for the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen. Brentuximab vedotin is administered by injection. About 80 percent of anaplastic large cell lymphoma patients are cured. The combination therapy is most effective if a patient's tumor cells contain a protein called ALK-1.

Burkitt Lymphoma

This B-cell subtype is considered to be highly aggressive. It usually appears as a lymphoma mass in the abdominal (stomach) area. It can also appear in bone marrow, blood, the central nervous system and other organs. Burkitt lymphoma, named after the surgeon who first identified the disease in children in Africa, mostly affects older adults. In Africa, the disease usually appears in children as a mass in a facial bone, especially the jaw. Doctors typically use chemotherapy to treat the disease. Drugs used include prednisone, cyclophosphamide (Cytoxan®), vincristine (Oncovin®), cytarabine (Cytosar-U®, cytosine arabinoside, ara-C), doxorubicin (Adriamycin® PFS, Adriamycin®) and methotrexate (Rheumatrex®, Trexall®).

Central Nervous System Lymphoma

There are two types of this rare central nervous system (CNS) lymphoma: primary and secondary. Primary CNS lymphoma starts in the brain or spinal cord and is an AIDS-associated lymphoma, although it may be related to other NHL subtypes as well. Secondary CNS lymphoma starts in another area of the body and spreads to the brain and/or spinal cord. Researchers are currently studying effective treatments for both types in clinical trials. Standard treatment may include chemotherapy, glucocorticosteroid drugs and/or radiation therapy. Treatment in clinical trials includes immunotherapy and high-dose chemotherapy with stem cell transplantation. Read more

Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive NHL subtype, making up about 30 percent of all NHL cases in the United States. It affects mostly middle-aged and older adults. Although it falls into the aggressive category, DLBCL can sometimes start out as an indolent lymphoma, such as small B-cell lymphoma or a follicular lymphoma. The chemotherapy regimen R-CHOP has proved successful in curing 50 percent to 60 percent of patients with DLBCL and is the standard of care for advanced-stage disease.

Mantle Cell Lymphoma

By the time mantle cell lymphoma is diagnosed, it's usually already widespread in the lymph nodes and bone marrow and sometimes in the liver, intestines and spleen. NHL develops in a lymphocyte in an area of a lymph node known as the mantle zone. Mantle cell lymphoma is most commonly diagnosed in men older than 50. Doctors typically treat mantle cell lymphoma with chemotherapy drugs and the monoclonal antibody rituximab (Rituxan®).

To read more about mantle cell lymphoma and treatment options, download or order The Leukemia & Lymphoma Society's (LLS's) free fact sheet Mantle Cell Lymphoma.

Peripheral T-Cell Lymphoma

Peripheral T-cell lymphoma is one of the most difficult lymphomas to treat. There are several forms of this subtype:

  • acute adult T-cell lymphoma (the most common)
  • extranodal T-cell or natural killer-cell (NK-cell) lymphoma
  • nasal type lymphoma, which often affects the upper-airway passages, such as the nose and nasopharynx, and skin and digestive tract
  • enteropathy type T-cell lymphoma, which can affect people sensitive to gluten
  • subcutaneous panniculitis-like T-cell lymphoma, which invades the skin's deepest levels, causing nodules to form under the skin

Peripheral T-cell lymphoma is usually treated like diffuse large B-cell lymphoma, usually with R-CHOP. However, studies are under way to develop more effective treatment approaches.

For more information about peripheral T-cell lymphoma and treatment options, download or order LLS's free fact sheet Peripheral T-Cell Lymphoma.

Transformed Follicular Lymphoma

Follicular lymphoma starts out as an indolent NHL subtype. However, it often transforms to an aggressive large B-cell lymphoma. High-dose chemotherapy followed by autologous stem cell transplantation can be an effective treatment to manage the disease.

A clinical trial can also be a good option for follicular lymphoma patients whose disease has transformed despite several different treatment approaches having been tried. Other treatment choices are:

  • chemotherapy with or without the monoclonal antibody rituximab (Rituxan®).
  • a radioimmunotherapeutic monoclonal antibody such as Zevalin®
  • radiation therapy
  • supportive care
  • combination chemotherapy with Rituxan and possibly radiation therapy for patients whose FL transformed before a significant amount of treatment and is in a single area
  • autologous stem cell infusion (in a clinical trial)

Treatment options for indolent FL and factors that affect treatment outcome are described in Treatment for Indolent NHL Subtypes.

last updated on Thursday, February 20, 2014

Get Information
& Support

Contact an Information Specialist.

Newly Diagnosed?